The Ozempic Question: A 600,000-Person Study Just Changed the Addiction Medicine Conversation

The drugs were designed for diabetes. Then weight loss. Now a study of more than 600,000 U.S. veterans, published earlier this month and covered by ScienceDaily, suggests they may also be fighting addiction.

People taking GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and related medications — were 14% less likely to develop a substance use disorder than comparable non-users. The reduction held across every substance class the researchers examined: alcohol (18%), cannabis (14%), cocaine (20%), nicotine (20%), and opioids (25%). Among people already struggling with addiction, GLP-1 users had fewer overdoses, fewer emergency department visits, and fewer drug-related deaths.

This is not a randomized trial. It is an observational study, which means the veterans who were prescribed GLP-1s likely differed from those who weren’t in ways the analysis couldn’t fully control for — metabolic health, healthcare access, engagement with the medical system. Those confounders matter. They don’t fully explain a signal this consistent across six substance categories.

The mechanistic story is plausible: GLP-1 receptors exist in the brain’s reward circuitry — the ventral tegmental area, the nucleus accumbens, regions where dopamine drives motivation and craving. Blocking those receptors may dampen the reward signal that addictive substances exploit. Researchers at Washington University in St. Louis made a similar argument in March 2026, finding that GLP-1 drugs appear to target a common biological pathway underlying multiple SUDs.

The randomized controlled trial evidence exists for one SUD so far. A double-blind RCT published in The Lancet in May 2026 — by Klausen, Justesen, Volkow, and colleagues — enrolled 108 adults with alcohol use disorder and comorbid obesity. Participants received once-weekly semaglutide (2.4mg) or placebo alongside standard cognitive behavioral therapy. Semaglutide significantly reduced heavy drinking days, drinks per drinking day, and self-reported cravings.

For stimulant use disorder specifically, two randomized trials are running now. The SHIFT Study (NCT07509112) started enrolling people with methamphetamine use disorder in May 2026; results expected early 2027. A separate RCT for cocaine use disorder (Yamamine, Schmitz et al.) published its protocol in PubMed in May 2026.

The question the field will need to answer: if these trials succeed, will GLP-1s for SUD be prescribed and covered? The history of evidence-based addiction treatments suggests that efficacy data alone isn’t enough — buprenorphine was approved in 2002 and took twenty years to normalize in primary care. If semaglutide works for meth and cocaine, the faster battle will be the policy one.

---

Follow our coverage of addiction pharmacotherapy developments on our Science & Medicine channel.